Russian regulatory authorities to implement a new strategy for imported medicines

As per the recent report of The Pharma Letter, the Russian government plans to allow access to imported medications that have not gone through the clinical trials in Russia.

This will be implemented to the medicines from USA, JAPAN, as well as countries of the European Union and will be part of the present roadmap "Development of Competition in Public Health," which has been newly authorized by the Russian government. This strategy will give native patients better access to new drugs. These medications labeled with declaring that the drug has not gone through clinical research in the Russian Federation. One of the primary reasons behind this plan is the time to launch a new drug into the Russian market that takes up to five years, out of which three years consumed into their clinical trials. However, this condition is supposed to change soon. Designed liberalization will not influence all the new medications provided to the Russian market, but initially, those the making of which analogues have not established in the country, and by the end of this year the plan on definitive principles of drug selection should be worked out. The most necessitated medications amongst Russian patients involve medicines against epilepsy, anti-cancer drug along with orphan medicines for the management of rare diseases. Possibly by the end of this year, the new strategy to be implemented is being planned.